Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Therapeutic strategies of urinary disorders in MS. Practice and algorithms.
Patients with multiple sclerosis show increased oxidative stress markers and somatic telomere length shortening.
Association of interleukin-1 gene polymorphisms with multiple sclerosis: a meta-analysis.
Drug therapy for multiple sclerosis.
We are about to cure multiple sclerosis in the next 10 years, even though we do not know its cause: Yes.
Novel Agents for Relapsing Forms of Multiple Sclerosis.
SIRT1 Deficiency in Microglia Contributes to Cognitive Decline in Aging and Neurodegeneration via Epigenetic Regulation of IL-1β.
Experience with Fingolimod in Clinical Practice.
Impact of delayed diagnosis and treatment in clinically isolated syndrome and multiple sclerosis.
High cumulative JC virus seroconversion rate during long-term use of natalizumab.
IFNβ secreted by microglia mediates clearance of myelin debris in CNS autoimmunity.
Retinal nerve fiber layer thickness and thalamus pathology in multiple sclerosis patients.
Deleterious versus protective autoimmunity in multiple sclerosis.
[Multimodal complex treatment in multiple sclerosis : Influence on motor performance and need of care.]
The TASK1 channel inhibitor A293 shows efficacy in a mouse model of multiple sclerosis.
Magnetic resonance imaging signatures of vascular pathology in multiple sclerosis.
Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells.
Primary Cutaneous Cryptococcus in a Patient With Multiple Sclerosis Treated With Fingolimod.
Glial Cell Development and Function in Zebrafish.
Effects of a resistance training program and subsequent detraining on muscle strength and muscle power in multiple sclerosis patients.
Cognitive impairment in relapsing remitting and secondary progressive multiple sclerosis patients: efficacy of a computerized cognitive screening battery.
Characterization of the interaction between astrocytes and encephalitogenic lymphocytes during the development of experimental autoimmune encephalitomyelitis (EAE) in mice.
The harm of ham hocks: Foreign body impaction in long-standing multiple sclerosis.
Cell fusion in the brain: two cells forward, one cell back.
A comparative analysis of Patient-Reported Expanded Disability Status Scale tools.
Pages
« first
‹ previous
…
261
262
263
264
265
266
267
268
269
…
next ›
last »